DRIO - NASDAQ

DarioHealth Corp.

DRIO·NASDAQ

$7.65

+3.7%

HealthcareMedical - Diagnostics & Research

DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario's metabolic solutions to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Musculoskeletal, which helps to prevent and treat the most common MSK conditions; Dario's behavioral health solution that optimizes access to evidence-based care; chronic condition management solutions; DarioEngage, a proprietary care management platform; and device-specific disposables test strip cartridges, lancets, and blood glucose monitoring systems. It also provides smart glucose meters; bluetooth connected blood pressure cuff; digital scales; biofeedback sensor devices; and diabetes management programs, including lifestyle changes, healthy eating, advanced tracking, and live coaching. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$55.94M

EPS1.2400

P/E Ratio6.17

Earnings Date08/11/2026

110.08M

Assets

-7%

3Y-8.0%

5Y+211.0%

10Y+2743.0%

42.15M

Total Liabilities

-10%

3Y+8.0%

5Y+481.0%

10Y+305.0%

67.92M

Total Equity

-6%

3Y-15.0%

5Y+141.0%

10Y-1138.0%

DarioHealth Corp. Funding & Solvency Profile

DRIO · NASDAQ

Current Assets

Cash & Cash Equivalents26.25M

Net Receivables2.67M

Inventory4.32M

Other Current Assets0.00

Total Current Assets35 M

Non-Current Assets

Property, Plant & Equipment0.00

Goodwill & Intangible Assets73.36M

Long-Term Investments80.00K

Other Non-Current Assets1.83M

Total Non-Current Assets2 M

Total Assets

110.08M

Financial Health Analysis

Current Ratio

3.73x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.62x

Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.

Working Capital

25 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

32% Current

Capital-intensive business with significant long-term investments in property, equipment, or intangibles.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

DarioHealth Corp. Balance Sheet

DRIO • NASDAQ

DarioHealth Corp. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	26.2M	27.8M	36.8M	49.4M	36M	28.6M	20.4M	11M	3.7M	1.1M	2.7M	1.5M	2.3M	1.2M
Short-Term Investments	0.0	697K	0.0	0.0	0.0	0.0	0.0	0.0	258K	225K	80K	83K	153.6K	21.6K
Cash & Short-Term Investments	26.2M	28.5M	36.8M	49.4M	36M	28.6M	20.4M	11M	4M	1.3M	2.8M	1.5M	2.4M	1.3M
Net Receivables	2.7M	5.4M	3.6M	6.4M	1.8M	1.7M	712K	234K	435K	290K	22K	33K	51.5K	71.4K
Accounts Receivables	2.1M	4.8M	3.2M	6.4M	1.3M	124K	672K	168K	282K	226K	0.0	0.0	51.5K	0.0
Other Receivables	527K	548K	488K	0.0	476K	1.6M	40K	66K	153K	64K	22K	33K	0.0	71.4K
Inventory	4.3M	4.8M	5.1M	8M	6.2M	2.3M	1.4M	1.4M	1.2M	888K	601K	234K	0.0	0.0
Prepaids	1.6M	1.8M	1.5M	908K	1.6M	1.4M	203K	454K	451K	440K	622K	159K	423.3K	330.1K
Other Current Assets	0.0	175K	292K	887K	0.0	187K	215K	251K	258K	0.0	291K	94K	0.0	13.4K
Total Current Assets	34.8M	40.5M	47.3M	65.5M	45.6M	34.1M	22.9M	13.3M	6M	2.9M	4.3M	2.1M	2.9M	1.7M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	0.0	1.8M	1.9M	2M	989K	1.1M	1.4M	733K	869K	901K	749K	978K	1.1M	617.4K
Goodwill	57.4M	57.4M	41.6M	41.6M	41.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Intangible Assets	15.9M	18.8M	5.4M	9.9M	12.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Goodwill & Intangible Assets	73.4M	76.2M	47M	51.6M	54.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Long-Term Investments	80K	0.0	6K	6K	20K	0.0	17K	43K	42K	35K	41K	0.0	0.0	0.0
Tax Assets	0.0	0.0	0.0	-6K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	1.8M	392K	143K	117K	57K	205K	200K	0.0	0.0	0.0	0.0	47K	41.2K	31.5K
Total Non-Current Assets	75.3M	78.4M	49.1M	53.7M	55.2M	1.3M	1.6M	776K	911K	936K	790K	1M	1.2M	648.9K
Total Assets	110.1M	118.9M	96.4M	119.2M	100.8M	35.4M	24.6M	14.1M	7M	3.9M	5.1M	3.1M	4.1M	2.3M
LIABILITIES
CURRENT LIABILITIES
Total Payables	2.9M	3M	1.1M	2.3M	5.1M	2.5M	1.7M	2.6M	1.9M	1.8M	978K	708K	586K	250.4K
Accounts Payable	2.9M	3M	1.1M	2.3M	5.1M	2.5M	1.7M	2.6M	1.9M	1.8M	978K	708K	586K	250.4K
Accrued Expenses	0.0	6.1M	2.2M	4.4M	3.4M	2.1M	887K	974K	1.2M	1.1M	247K	205K	328.7K	232.3K
Short Term Debt	430K	5.5M	4M	8.8M	266K	0.0	317K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	504K	111K	293K	0.0	310K	317K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	714K	1.6M	997K	1.3M	1.2M	1.2M	1.2M	736K	0.0	0.0	31K	24K	0.0	0.0
Other Current Liabilities	5.3M	0.0	4.1M	2.2M	4.4M	880K	820K	880K	0.0	0.0	434K	679K	591.4K	84.1K
Total Current Liabilities	9.3M	16.6M	12.5M	19.4M	14.4M	7M	5.2M	5.2M	3M	2.9M	1.7M	1.6M	1.5M	566.8K
NON-CURRENT LIABILITIES
Long Term Debt	30.7M	23.5M	24.6M	18.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	1.5M	6M	276K	910K	825K	0.0	0.0	0.0	1K	7.5M	2.6M	4M	2.7M	2.8M
Total Non-Current Liabilities	32.8M	30.2M	25.8M	19.8M	846K	222K	455K	0.0	1K	7.5M	2.6M	4M	2.7M	2.8M
Capital Lease Obligations	571K	1.3M	996K	1.1M	21K	532K	772K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	42.2M	46.9M	38.2M	39.2M	15.2M	7.3M	5.7M	5.2M	3M	10.4M	4.3M	5.6M	4.2M	3.4M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.4M	2.8M	0.0	0.0
Common Stock	4K	4K	3K	3K	2K	0.0	0.0	8K	7K	6K	5K	2K	2K	1.5K
Additional Paid-In Capital	520M	462.4M	407.5M	365.8M	307.6M	171.4M	129M	98.2M	74.9M	48.4M	41.8M	30.8M	19.9M	5M
Retained Earnings	-452.1M	-390.3M	-349.4M	-285.9M	-222M	-143.2M	-110.1M	-89.3M	-71M	-55M	-43.4M	-36.1M	-20M	-6.1M
Accumulated Other Comprehensive Income/Loss	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-440K	-477K	-286K	-432K	-97K	-824.9K	-24.8K
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	286K	0.0	0.0	0.0	26K
Total Stockholders' Equity	67.9M	72M	58.1M	80M	85.5M	28.2M	18.9M	8.9M	3.9M	-6.5M	777K	-2.5M	-86.4K	-1.1M
Total Equity	67.9M	72M	58.1M	80M	85.5M	28.2M	18.9M	8.9M	3.9M	-6.5M	777K	-2.5M	-86.4K	-1.1M
SUMMARY
Total Liabilities & Equity	110.1M	118.9M	96.4M	119.2M	100.8M	35.4M	24.6M	14.1M	7M	3.9M	5.1M	3.1M	4.1M	2.3M
Total Investments	80K	697K	6K	6K	20K	0.0	17K	43K	258K	260K	121K	83K	153.6K	21.6K
Total Debt	31.7M	30.2M	29.5M	28M	287K	532K	772K	0.0	0.0	0.0	2.4M	2.8M	0.0	0.0
Net Debt	5.5M	2.4M	-7.3M	-21.3M	-35.7M	-28.1M	-19.6M	-11M	-3.7M	-1.1M	-314K	1.3M	-2.3M	-1.2M
Shares Outstanding	45,497,000	45,497,000	45,497,000	45,497,000	45,497,000	45,497,000	45,497,000	45,497,000	45,497,000	45,497,000	45,497,000	45,497,000	45,497,000	45,497,000

SEC Filings

DRIO - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 13, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 13, 2026	April 10, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 30, 2026	March 30, 2026	2026	View Filing
S-3 S-3 N/A	March 19, 2026	March 19, 2026		View Filing
10-K 10-K 2025 FY FY	March 19, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 02, 2026	February 02, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 29, 2026	January 29, 2026	2026	View Filing
S-3/A S-3/A (Amended) N/A	December 29, 2025	December 29, 2025		View Filing
DEF 14A DEF 14A 2026 N/A	December 22, 2025	January 29, 2026	2026	View Filing
10-Q 10-Q 2025 Q3 Q3	November 13, 2025	September 30, 2025	2025	View Filing

Showing 1 to 10 of 257 filings

Related Guides

Blog Categories

Continue your DRIO research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.